title: Mitral valve involvement as a predominant feature of cardiac amyloidosis.
abstract: Cardiac involvement in systemic amyloidosis carries poor prognosis with a median survival of 5 months.(1) The authors report an unusual presentation of cardiac amyloidosis in the form of predominant mitral regurgitation. The patient responded very well to medical therapy with subsequent improvement of mitral valve dysfunction. The authors would like to highlight this multisystem involvement and the presence of a complex overlap of systemic features.
authors: Institute of Cellular Medicine, Newcastle upon Tyne, UK. girishviswa@gmail.com
authors: Girish
authors: G
authors: Viswanathan
authors: James
authors: J
authors: Williams
authors: Simon
authors: S
authors: Slinn
authors: Philip
authors: P
authors: Campbell
mesh_terms: D000328:Adult; D000682:Amyloid / Q000032:analysis / Q000378:metabolism*; D000686:Amyloidosis / Q000175:diagnosis* / Q000188:drug therapy; D001707:Biopsy, Needle; D001774:Blood Chemical Analysis; D001795:Blood Pressure Determination / Q000379:methods; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000175:diagnosis / Q000209:etiology; D004452:Echocardiography / Q000379:methods; D004562:Electrocardiography / Q000379:methods; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008944:Mitral Valve Insufficiency / Q000175:diagnosis* / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000682:Amyloid; D003907:Dexamethasone; D003520:Cyclophosphamide